Irritable Bowel Disease, or IBD, refers to a group of incurable chronic diseases of the intestinal tract.
As many as 4 million people (including 250,000 Canadians and 1,000,000 Americans) worldwide
suffer from a form IBD. Seaford Pharmaceuticals and its associates have taken great interest in
researching the etiology of the disease. The Gastroenterology line of products has been carefully
developed to address the needs of IBD patients with the most current evidence-based modalities.
Of particular interest to Seaford is Irritable Bowel Syndrome, a chronic functional disorder of the
colon plaguing upto 20% of Canadian population (Thompson et al. Gastroenterology Int. 1992; 5:75-91).
IBS causes a great deal of discomfort and distress, and can be disabling or seriously compromise a
person's quality of life. Seaford offers a range of therapeutics specifically aimed at providing IBD
sufferers with symptomatic relief. |
